Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
*Driving Forces: Risk Capital_Angel, Venture (VC), Strategic Corporate( CVC), Private Equity (PE), Mergers and Acquisition (M&A) (Trends)
*Driving Forces: Risk Capital_Angel, Venture (VC), Strategic Corporate( CVC), Private Equity (PE), Mergers and Acquisition (M&A) (Facts & Figures)
Venture-Geographic Data
*Bioscience Regional Clusters & HotSpots
*Industry: Northern California & Silicon Valley
Vera Therapeutics, Inc. (NASDAQ: VERA)*

Organization & Developments: Vera Therapeutics

Parents

*The firm is a clinical stage biopharma developing a treatment for the kidney diseases IgAN and Lupus Nephritis.
2021: Biotech Analysis Central Preview Series: Vera Therapeutics
2022: Vera Therapeutics: Under The Radar IgAN Player Has Much To Prove_seekingalpha.com
2024: Analysts hail Vera's kidney drug as potential 'functional cure' as benefits persist to Week 96
2024: Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases
2024: Vera Therapeutics Breaks Out On Promising Results For Kidney Drug
2024: Vera Therapeutics: Soaring On IgAN Data, But Full Approval A Distant Prospect
2024: Vera Therapeutics: Strong Data In IgAN, But We May Be Too Late
2024: Vera Therapeutics: Waiting For A Pullback_ seekingalpha.com
2024: Vera: Potential First Of Atacicept As A B-Cell Modulator For IgAN Patients
2025: Otsuka bests Vera Therapeutics in kidney disease showdown
2025: Vera Therapeutics Lands Massive $500M Financing Deal as FDA Filing for Kidney Drug Approaches
2025: Vera Therapeutics reports positive results from trial of kidney disease drug
2025: Vera Therapeutics: Does The Earlier Otsuka Launch Harm Its Prospects Much?
2025: Vera Therapeutics: Huge Catalyst Upcoming For Kidney Disease Drug
2026: #10 Atacicept, Company: Vera Therapeutics Used for: IgA nephropathy Est. 2032 sales: $1.7 billion